Ultragenyx Pharmaceutical Inc. (RARE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 250M 500M 750M FY24: 560M FY25: 673M FY24 FY25

Gross Profit Annual

0 20M 40M 60M FY17: 2.6M FY18: 50.3M FY17 FY18

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-600M -400M -200M 0 200M 400M 600M FY24: -536M FY25: -535M FY24 FY25

Net Income Annual

-600M -400M -200M 0 200M 400M 600M FY24: -569M FY25: -575M FY24 FY25

Cost of Revenue Annual

0 400K 800K 1.2M FY17: 1K FY18: 1.1M FY17 FY18

Operating Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY24: -414M FY25: -466M FY24 FY25

Free Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY24: -421M FY25: -472M FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 35M 70M 105M FY24: 90.5M FY25: 98.6M FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '24: -6.39 Q4 '24: -6.33 Q1 '25: -5.87 Q2 '25: -5.52 Q3 '25: -5.93 Q4 '25: -5.83 Q1 '26: -6.10 Q2 '26: -5.83 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.